Efficacy evaluation of polysaccharide nucleic acid-fraction of BCG on vasomotor rhinitis / 临床耳鼻咽喉头颈外科杂志
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
; (24): 201-203, 2008.
Article
de Zh
| WPRIM
| ID: wpr-747533
Bibliothèque responsable:
WPRO
ABSTRACT
OBJECTIVE@#To investigate the efficacy and safety of polysaccharide nucleic acid-fraction (BCG-PSN) in the treatment of vasomotor rhinitis.@*METHOD@#Sixty patients were randomly divided into BCG-PSN group (n = 30) and control group (n = 30). The patients in BCG-PSN group were administered with BCG-PSN 1.0 mg twice a week for two months, and intranasal azelastine was used if needed. The patients in control group were administered with intranasal azelastine solely twice a day, which could be decreased with the symptom relief. Follow-up was 6 months. Symptom and medication scores were recorded. Side effects were registered.@*RESULT@#The symptom and medication scores of BCG-PSN group were significantly lower than that of control group (P 0.05), while the medication score of BCG-PSN group was still much lower than that of control group (P < 0.01). No serious adverse events were reported in BCG-PSN group except for local pain on the injection place in one patient.@*CONCLUSION@#BCG-PSN is effective and safe in the treatment of vasomotor rhinitis.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Vaccin BCG
/
Méthode en simple aveugle
/
Rhinite vasomotrice
/
Utilisations thérapeutiques
/
Traitement médicamenteux
Type d'étude:
Clinical_trials
Limites du sujet:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
langue:
Zh
Texte intégral:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
Année:
2008
Type:
Article